Clinical Cardiology Alert – February 1, 2023
February 1, 2023
View Issues
-
Does the Completeness of Coronary Revascularization Affect the Outcome of Transcatheter Aortic Valve Replacement?
In this study of data from the REVASC TAVI registry, completeness of myocardial revascularization did not significantly affect the risk of all-cause mortality or the combined endpoint of death, stroke, myocardial infarction, or heart failure hospitalization at two years.
-
Outcomes for Patients Undergoing Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation
Researchers analyzed transcutaneous mitral valve repair in patients with moderate-to-severe or worse mitral valve regurgitation caused by cardiomyopathy and heart failure despite maximally tolerated guideline-directed medical therapy. Compared to medical therapy alone, undergoing repair resulted in fewer heart failure and other cardiovascular disease hospitalizations and significantly more time free of hospitalization and death.
-
Ablation vs. Drug Therapy for Atrial Fibrillation, Revisited
A three-year follow-up of EARLY-AF, a study of relatively young and healthy patients with recent atrial fibrillation, showed cryoablation remains superior to drug therapy for preventing the development of persistent atrial fibrillation.
-
Is Chlorthalidone Superior to Hydrochlorothiazide for Treating Hypertension?
Randomly switching half of patients with hypertension on hydrochlorothiazide to chlorthalidone did not produce any difference in major cardiovascular outcomes.
-
An Easy Measure of Potentially Harmful Salt Intake
Those who rarely or never added salt to their food and strongly adhered to the Dietary Approaches to Stop Hypertension diet exhibited the lowest incidence of subsequent cardiovascular disease.